InvestorsHub Logo
Followers 138
Posts 23702
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Thursday, 10/05/2017 6:53:01 AM

Thursday, October 05, 2017 6:53:01 AM

Post# of 403478

Innovation has successfully completed a Phase 2 clinical trial of Prurisol in patients with mild-to-moderate Chronic Plaque Psoriasis. Overall analyses showed (pdf) the drug to appear safe, well-tolerated and efficacious in the highest dosing arm across 12 weeks of treatment. Patients with more moderate forms of psoriasis saw the greatest clinical improvements. Pharmacokinetic data further revealed an early and dose-dependent response that improved as treatment duration increased.

“A NEW ORAL PSORIASIS DRUG THAT DELIVERS
SUBSTANTIAL EFFICACY WOULD BENEFIT PATIENTS AND COMMAND CONSIDERABLE MARKET VALUE.”
— Dr. Arthur Bertolino
Innovation has completed enrollment in a Phase 2b trial of Prurisol in moderate-to-severe Chronic Plaque Psoriasis, assessing the drug's efficacy at higher dosing regimens.

Due to its mechanism of action, Prurisol may also have applicability in treating other autoimmune-based diseases, such as Psoriatic Arthritis and Rheumatoid Arthritis.



Good luck and GOD bless,

George
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News